Brief Title
Breathing Training to Improve Human Performance at High Altitude
Official Title
Breathing Training to Improve Human Performance at High Altitude
Brief Summary
Individuals traveling to altitudes above 8,000 feet may suffer from impaired exercise and cognitive performance, and acute mountain sickness (AMS). Decreased barometric pressure, which leads to low blood oxygen levels, is the primary cause of these disorders. Symptoms of AMS are characterized by headache, nausea, vomiting, dizziness, fatigue, and difficulty sleeping. The goal of this research is to identify whether Respiratory Muscle Training will improve physical and cognitive performance, and reduce the symptoms of AMS, at simulated high altitude.
Study Type
Interventional
Primary Outcome
Change in exercise performance during acute simulated high-altitude exposure as measured by a peak oxygen uptake test and time to complete a 720kJ (40km) time trial on a Velotron cycle ergometer.
Condition
Mountain Sickness Acute
Intervention
Respiratory Muscle Training
Study Arms / Comparison Groups
Respiratory Muscle Training
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
28
Start Date
August 9, 2018
Completion Date
January 15, 2020
Primary Completion Date
January 15, 2020
Eligibility Criteria
Inclusion Criteria: - Healthy - Men, ages 18-45 who are able to achieve at least 3.5 watts/kg of body weight during the peak oxygen uptake test Exclusion Criteria: - Less than 18 years old - Greater than 45 years old - Have a body mass index greater than or equal to 30 - Have been recent smokers (tobacco or e-cigarettes) - Current recreational or medical marijuana users - Currently taking any medication (over-the-counter or prescription) or herbal supplements - Participants who are unable to tolerate drinking only two, 6-ounce caffeinated beverages per day of the study - Participants who are legally blind - Participants who have been to altitudes above Denver (1609m or 5280ft), including air travel, in the 3 weeks prior to the start of the study or with plans to do so during the study - Participants who have suffered a significant head injury, have anemia or sickle cell trait or disease, have active peptic ulcer disease, diabetes, hypertension, heart disease, HIV/AIDS, glaucoma, kidney disease, liver disease/cirrhosis, adrenal gland failure, hyponatremia/hypokalemia, tuberculosis - Participants who have a current herpes infection or any other current type of viral or bacterial infection - Participants with seizure disorders or history of migraines
Gender
Male
Ages
18 Years - 45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
Robert Roach, PhD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT03530163
Organization ID
18-0464
Responsible Party
Sponsor
Study Sponsor
University of Colorado, Denver
Collaborators
United States Department of Defense
Study Sponsor
Robert Roach, PhD, Principal Investigator, Director, Altitude Research Center
Verification Date
April 2022